Krka dd 2024 IR
The report highlights Krka Group's record-breaking financial performance in 2024, generating ’1.9 billion in revenue (up 6% year-on-year) and a net profit of ’356 million. The company achieved a record production volume of 18.9 billion tablets and capsules and expanded its portfolio with 22 new products. Notably, Krka published its first sustainability report under ESRS standards and achieved an improved S&P Global CSA score of 56, ranking among the top 10% in the pharmaceutical industry. Additionally, Krka established a joint venture in India, Krka Pharma Pvt. Ltd., to build a new production plant in Hyderabad.
Company: Krka dd
Sector: Health Care
Country: Slovenia
Year: 2024
Type: IR
Pages: 402
Krka dd
Annual Report
The report highlights Krka Group's record-breaking financial performance in 2024, generating ’1.9 billion in revenue (up 6% year-on-year) and a net profit of ’356 million. The company achieved a record production volume of 18.9 billion tablets and capsules and expanded its portfolio with 22 new products. Notably, Krka published its first sustainability report under ESRS standards and achieved an improved S&P Global CSA score of 56, ranking among the top 10% in the pharmaceutical industry. Additionally, Krka established a joint venture in India, Krka Pharma Pvt. Ltd., to build a new production plant in Hyderabad.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees